Eptifibatide Peptide: Integrilin, GP IIb/IIIa Inhibition and Safety
Eptifibatide (Integrilin) is an approved IV GP IIb/IIIa inhibitor peptide for acute coronary syndromes and PCI. Mechanism, trial evidence, dosing and safety.
Eptifibatide, sold under the brand name Integrilin, is a peptide drug with an evidence profile that sits far from the research-market wellness peptides. It is an FDA-approved, hospital-administered intravenous medicine used in cardiology to prevent blood clots during acute coronary syndromes and coronary procedures. It is also a striking example of nature-derived peptide design: its active core is copied from snake venom.
This guide is educational and not medical advice. Eptifibatide is a prescription, in-hospital infusion drug given under continuous monitoring. It should only be started, dosed, adjusted or stopped by qualified clinical teams following the product label and patient-specific factors.
If you are new to this drug class, it helps to start with what peptides are and the peptide half-life guide, because eptifibatide's short half-life is central to how it is used and why its effect wears off quickly after the infusion stops.
Eptifibatide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic cyclic heptapeptide that inhibits the platelet GP IIb/IIIa receptor. |
| Brand name | Integrilin, plus generic eptifibatide injection products. |
| Origin | Active KGD pharmacophore derived from barbourin, a disintegrin in southeastern pygmy rattlesnake venom. |
| Route | Intravenous only (bolus plus continuous infusion), used in hospital. |
| Approved uses | Acute coronary syndrome and percutaneous coronary intervention (PCI). |
| Main effect | Reversible blockade of platelet aggregation at its final common pathway. |
| Plasma half-life | Approximately 2.5 hours; platelet function recovers about 4 to 8 hours after stopping. |
| Main safety frame | Bleeding-dominated, with thrombocytopenia and renal-based dosing limits. |
How A GP IIb/IIIa Inhibitor Works
Platelets carry a surface receptor called glycoprotein IIb/IIIa (integrin alpha-IIb beta-3). When platelets are activated, this receptor changes shape and binds fibrinogen and von Willebrand factor. Those adhesive proteins then bridge platelets together. This cross-linking is the final common pathway of platelet aggregation, regardless of what triggered the platelet in the first place.
Eptifibatide is a high-affinity, reversible antagonist of GP IIb/IIIa. By occupying the receptor, it prevents fibrinogen from binding and stops platelets from clumping into a growing thrombus. Because it acts at the last step, it blocks aggregation more completely than upstream agents such as aspirin, which only addresses one activation pathway.
The molecular design is what makes eptifibatide notable as a peptide. Its active sequence is a Lys-Gly-Asp (KGD) motif, a variant of the better-known RGD integrin-binding sequence. That KGD pharmacophore is derived from barbourin, a disintegrin isolated from the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Researchers cyclized and stabilized this sequence into a compact, selective heptapeptide. The result is a drug that mimics how the venom protein disrupts platelet integrins, but in a controlled, dosable form.
Two pharmacology features matter clinically. First, binding is reversible, so when the infusion stops, eptifibatide dissociates from the receptor and platelet function returns. Second, the drug is cleared largely by the kidneys, so renal function strongly affects exposure. The plasma elimination half-life is about 2.5 hours, and clearance falls in patients with renal insufficiency and in advanced age.
Approved Uses And Reference Dosing
Eptifibatide is approved by the FDA, with the original Integrilin approval in 1998. The labeled indications are the treatment of acute coronary syndrome (ACS), including patients managed medically and those undergoing PCI, and the treatment of patients undergoing PCI, including intracoronary stenting.
The reference figures below are taken from the prescribing information and major trials. They describe how the drug has been studied and labeled. They are not recommendations, and they are not a protocol for self-use. Eptifibatide is an in-hospital infusion managed alongside aspirin, heparin and other antiplatelet therapy.
| Setting | Reference regimen from labeling/trials | Note |
|---|---|---|
| Acute coronary syndrome | 180 mcg/kg intravenous bolus, then a continuous infusion of 2 mcg/kg/min, continued up to 72 to 96 hours. | Given with aspirin and heparin per label. |
| Percutaneous coronary intervention | 180 mcg/kg bolus, then 2 mcg/kg/min infusion, with a second 180 mcg/kg bolus 10 minutes after the first. | The ESPRIT double-bolus regimen. |
| Renal impairment | Reduced infusion rate (1 mcg/kg/min) in moderate renal impairment per labeling. | Contraindicated in dialysis-dependent patients. |
These numbers are weight-based and time-limited because eptifibatide is a short-acting, continuously infused agent. That is the opposite of a depot or long-acting peptide. The drug's effect exists essentially only while it is being delivered, which is exactly what cardiologists want during a high-risk window.
What The Evidence Shows
Eptifibatide has an unusually deep randomized-trial base for a peptide drug, and the honest reading is that it is effective but with a meaningful bleeding tradeoff and a benefit that has narrowed in the modern era.
The landmark ACS trial was PURSUIT, published in the New England Journal of Medicine in 1998. It randomized roughly 10,900 patients with non-ST-elevation acute coronary syndromes and reported a statistically significant absolute reduction of about 1.5 percent in the 30-day rate of death or nonfatal myocardial infarction with eptifibatide versus placebo. That is a real but modest benefit, and it came with more bleeding.
In the PCI setting, IMPACT-II (Lancet, 1997) tested eptifibatide during coronary intervention in about 4,010 patients. The doses used achieved only roughly 50 to 60 percent platelet inhibition, and the benefit over aspirin was modest, suggesting higher dosing was needed. ESPRIT (Lancet, 2000) answered that with a double-bolus regimen in planned coronary stenting and cut the primary composite endpoint from about 10.5 percent to 6.6 percent, a clear improvement that established the modern PCI dose.
The picture became more nuanced with EARLY-ACS (New England Journal of Medicine, 2009). This trial compared routine early eptifibatide against a delayed, provisional strategy in higher-risk ACS patients already managed invasively. It did not show a significant benefit for routine early use and was associated with more bleeding. In contemporary practice, with potent oral antiplatelet agents widely available, GP IIb/IIIa inhibitors like eptifibatide are often reserved for selected situations rather than used universally.
The limit to keep in mind is that all of this evidence is hospital evidence, generated in monitored cardiac patients receiving concurrent anticoagulation. None of it supports any use outside that setting.
Safety And Contraindications
Eptifibatide's safety profile follows directly from its mechanism. A drug that powerfully blocks platelet aggregation will, by design, increase bleeding. The prescribing information centers on this.
| Safety issue | Why it matters |
|---|---|
| Major bleeding | The most common and most serious risk, including access-site, gastrointestinal and intracranial bleeding. |
| Thrombocytopenia | Eptifibatide can cause acute, sometimes profound drops in platelet count; counts are monitored. |
| Renal clearance | Cleared by the kidneys, so impaired renal function raises exposure and bleeding risk; dialysis dependence is a contraindication. |
| Active bleeding | Contraindicated with active abnormal bleeding within the prior 30 days. |
| Severe hypertension | Contraindicated in severe uncontrolled hypertension due to bleeding risk. |
| Recent stroke or surgery | Contraindicated with recent stroke, or recent major surgery, given hemorrhage risk. |
| Concurrent therapy | Used with heparin and aspirin, which compounds bleeding risk and demands monitoring. |
Because platelet inhibition is reversible, one practical advantage is that stopping the infusion allows platelet function to recover over roughly 4 to 8 hours, which helps if urgent surgery or bleeding management is needed. Even so, this is a drug whose entire risk-benefit balance depends on the controlled hospital environment in which it is given.
How To Evaluate An Eptifibatide Claim
Because eptifibatide is a "peptide" with a snake-venom backstory, it sometimes appears in peptide marketing contexts where it does not belong. A few questions separate legitimate clinical information from misuse.
First, is the source describing in-hospital intravenous cardiology use? That is the only context the evidence supports. Any framing of eptifibatide as a self-administered or wellness peptide is a red flag.
Second, does the claim acknowledge bleeding and thrombocytopenia? A description of a potent antiplatelet drug that omits its central risk is incomplete.
Third, does it respect the short half-life and continuous infusion model? Eptifibatide is not a depot, not a take-home injection and not comparable to long-acting peptides. The peptide half-life concept is the whole point here.
It also helps to remember that "peptide" is a chemical category, not a safety category. Eptifibatide sits alongside other approved peptide medicines that are strictly clinical tools, such as the somatostatin analog octreotide, the bradykinin-receptor blocker icatibant for hereditary angioedema, and even the obstetric and behavioral peptide oxytocin. Each works through a distinct receptor system and carries its own risk profile. None of them are interchangeable, and none should be reduced to a generic "peptide protocol."
Bottom Line
Eptifibatide (Integrilin) is a genuine, FDA-approved peptide medicine with a clear mechanism and a deep randomized-trial record. It is a reversible GP IIb/IIIa inhibitor that blocks the final common pathway of platelet aggregation, and its active sequence is elegantly derived from snake-venom disintegrin biology. In acute coronary syndromes and PCI, trials such as PURSUIT and ESPRIT established meaningful reductions in ischemic events.
The same potency defines its limits. Bleeding and thrombocytopenia are the dominant risks, renal function drives dosing, and the benefit in routine modern use has narrowed as oral antiplatelet therapy improved. Eptifibatide is an intravenous, in-hospital, monitored drug used in cardiac care. It is not a wellness peptide, not a self-administered product and not something to interpret outside its prescribing information and a clinician's judgment.
References
StatPearls, NCBI Bookshelf. Eptifibatide.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (NEJM, 1998).
Harrington RA, et al. Design and methodology of the PURSUIT trial (PMID 9291244).
IMPACT-II Investigators. Randomised placebo-controlled trial of eptifibatide on complications of PCI: IMPACT-II (Lancet, 1997).
ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) (Lancet, 2000).
Giugliano RP, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes: EARLY-ACS (NEJM, 2009).
Phillips DR, Scarborough RM. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa (PMID 11139832).
Tcheng JE, et al. Clinical pharmacology of eptifibatide (PMID 9291241).